Literature DB >> 24899643

The challenging world of cytopenias: distinguishing myelodysplastic syndromes from other disorders of marrow failure.

Amy E DeZern1, Mikkael A Sekeres2.   

Abstract

Over the past decade, our understanding of bone marrow failure has advanced considerably. Marrow failure encompasses multiple overlapping diseases, and there is increasing availability of diagnostic tools to distinguish among the subtypes. Identification of genetic alterations that underlie marrow failure has also greatly expanded, especially for myelodysplastic syndromes. Molecular markers are increasingly used to guide the management of myelodysplasia and may distinguish this diagnosis from other marrow failure disorders. This review summarizes the current state of distinguishing among causes of marrow failure and discusses the potential uses of multiple diagnostic and prognostic indicators in the management of myelodysplastic syndromes and other bone marrow failure disorders. ©AlphaMed Press.

Entities:  

Keywords:  Aplastic anemia; Bone marrow failure; Large granular leukemia; Molecular markers; Myelodysplastic syndrome; PNH; SNP array

Mesh：

Year:  2014        PMID： 24899643      PMCID： PMC4077450          DOI： 10.1634/theoncologist.2014-0056

Source DB:  PubMed          Journal:  Oncologist        ISSN： 1083-7159


  108 in total

1.  Relative increase of granulocytes with a paroxysmal nocturnal haemoglobinuria phenotype in aplastic anaemia patients: the high prevalence at diagnosis.

Authors:  H Wang; T Chuhjo; H Yamazaki; S Shiobara; M Teramura; H Mizoguchi; S Nakao
Journal:  Eur J Haematol       Date:  2001-03       Impact factor: 2.997

2.  Malignancies and survival patterns in the National Cancer Institute inherited bone marrow failure syndromes cohort study.

Authors:  Blanche P Alter; Neelam Giri; Sharon A Savage; June A Peters; Jennifer T Loud; Lisa Leathwood; Ann G Carr; Mark H Greene; Philip S Rosenberg
Journal:  Br J Haematol       Date:  2010-04-30       Impact factor: 6.998

3.  Somatic point mutations in RUNX1/CBFA2/AML1 are common in high-risk myelodysplastic syndrome, but not in myelofibrosis with myeloid metaplasia.

Authors:  David P Steensma; Richard J Gibbons; Ruben A Mesa; Ayalew Tefferi; Douglas R Higgs
Journal:  Eur J Haematol       Date:  2005-01       Impact factor: 2.997

4.  TERC and TERT gene mutations in patients with bone marrow failure and the significance of telomere length measurements.

Authors:  Hong-Yan Du; Elena Pumbo; Jennifer Ivanovich; Ping An; Richard T Maziarz; Ulrike M Reiss; Deborah Chirnomas; Akiko Shimamura; Adrianna Vlachos; Jeffrey M Lipton; Rakesh K Goyal; Frederick Goldman; David B Wilson; Philip J Mason; Monica Bessler
Journal:  Blood       Date:  2008-10-17       Impact factor: 22.113

5.  Paroxysmal nocturnal hemoglobinuria cells in patients with bone marrow failure syndromes.

Authors:  D E Dunn; P Tanawattanacharoen; P Boccuni; S Nagakura; S W Green; M R Kirby; M S Kumar; S Rosenfeld; N S Young
Journal:  Ann Intern Med       Date:  1999-09-21       Impact factor: 25.391

6.  SF3B1 haploinsufficiency leads to formation of ring sideroblasts in myelodysplastic syndromes.

Authors:  Valeria Visconte; Heesun J Rogers; Jarnail Singh; John Barnard; Manoj Bupathi; Fabiola Traina; James McMahon; Hideki Makishima; Hadrian Szpurka; Anna Jankowska; Andres Jerez; Mikkael A Sekeres; Yogen Saunthararajah; Anjali S Advani; Edward Copelan; Haruhiko Koseki; Kyoichi Isono; Richard A Padgett; Sami Osman; Kazunori Koide; Christine O'Keefe; Jaroslaw P Maciejewski; Ramon V Tiu
Journal:  Blood       Date:  2012-07-23       Impact factor: 22.113

7.  How I treat LGL leukemia.

Authors:  Thierry Lamy; Thomas P Loughran
Journal:  Blood       Date:  2010-12-29       Impact factor: 22.113

8.  Analysis of risk factors for myelodysplasias, leukemias and death from infection among patients with congenital neutropenia. Experience of the French Severe Chronic Neutropenia Study Group.

Authors:  Jean Donadieu; Thierry Leblanc; Brigitte Bader Meunier; Mohamed Barkaoui; Odile Fenneteau; Yves Bertrand; Micheline Maier-Redelsperger; Marguerite Micheau; Jean Louis Stephan; Noel Phillipe; Pierre Bordigoni; Annie Babin-Boilletot; Philippe Bensaid; Anne Marie Manel; Etienne Vilmer; Isabelle Thuret; Stephane Blanche; Eliane Gluckman; Alain Fischer; Françoise Mechinaud; Bertrand Joly; Thierry Lamy; Olivier Hermine; Bruno Cassinat; Christine Bellanné-Chantelot; Christine Chomienne
Journal:  Haematologica       Date:  2005-01       Impact factor: 9.941

9.  CUX1 is a haploinsufficient tumor suppressor gene on chromosome 7 frequently inactivated in acute myeloid leukemia.

Authors:  Megan E McNerney; Christopher D Brown; Xiaoyue Wang; Elizabeth T Bartom; Subhradip Karmakar; Chaitanya Bandlamudi; Shan Yu; Jinkyung Ko; Barry P Sandall; Thomas Stricker; John Anastasi; Robert L Grossman; John M Cunningham; Michelle M Le Beau; Kevin P White
Journal:  Blood       Date:  2012-12-03       Impact factor: 22.113

10.  Colony growth characteristics in chronic myelomonocytic leukemia.

Authors:  K Geissler; W Hinterberger; P Bettelheim; O Haas; K Lechner
Journal:  Leuk Res       Date:  1988       Impact factor: 3.156
View more
  9 in total

1.  Programmable 3D silk bone marrow niche for platelet generation ex vivo and modeling of megakaryopoiesis pathologies.

Authors:  Christian A Di Buduo; Lindsay S Wray; Lorenzo Tozzi; Alessandro Malara; Ying Chen; Chiara E Ghezzi; Daniel Smoot; Carla Sfara; Antonella Antonelli; Elise Spedden; Giovanna Bruni; Cristian Staii; Luigi De Marco; Mauro Magnani; David L Kaplan; Alessandra Balduini
Journal:  Blood       Date:  2015-01-09       Impact factor: 22.113

Review 2.  Assessing clonal haematopoiesis: clinical burdens and benefits of diagnosing myelodysplastic syndrome precursor states.

Authors:  Lukasz P Gondek; Amy E DeZern
Journal:  Lancet Haematol       Date:  2019-12-03       Impact factor: 18.959

3.  Large granular lymphocytic leukemia cured by allogeneic stem cell transplant: a case report.

Authors:  Edward Carey; Nicholas Ward; Maher Abdul-Hay
Journal:  J Med Case Rep       Date:  2022-06-08

Review 4.  Genetic Predisposition to Myelodysplastic Syndrome in Clinical Practice.

Authors:  Kristen E Schratz; Amy E DeZern
Journal:  Hematol Oncol Clin North Am       Date:  2020-01-06       Impact factor: 3.722

5.  Circulating exosomal microRNAs in acquired aplastic anemia and myelodysplastic syndromes.

Authors:  Valentina Giudice; Lauren G Banaszak; Fernanda Gutierrez-Rodrigues; Sachiko Kajigaya; Reema Panjwani; Maria Del Pilar Fernandez Ibanez; Olga Rios; Christopher K Bleck; Erin S Stempinski; Diego Quinones Raffo; Danielle M Townsley; Neal S Young
Journal:  Haematologica       Date:  2018-04-19       Impact factor: 9.941

Review 6.  Bone Marrow Failure Syndromes, Overlapping Diseases with a Common Cytokine Signature.

Authors:  Valentina Giudice; Chiara Cardamone; Massimo Triggiani; Carmine Selleri
Journal:  Int J Mol Sci       Date:  2021-01-12       Impact factor: 5.923

Review 7.  Hypoplastic Myelodysplastic Syndromes: Just an Overlap Syndrome?

Authors:  Bruno Fattizzo; Fabio Serpenti; Wilma Barcellini; Chiara Caprioli
Journal:  Cancers (Basel)       Date:  2021-01-03       Impact factor: 6.639

8.  A Deep Learning Model for the Automatic Recognition of Aplastic Anemia, Myelodysplastic Syndromes, and Acute Myeloid Leukemia Based on Bone Marrow Smear.

Authors:  Meifang Wang; Chunxia Dong; Yan Gao; Jianlan Li; Mengru Han; Lijun Wang
Journal:  Front Oncol       Date:  2022-04-14       Impact factor: 5.738

9.  Immunoexpression of CD34, CD117, and p53 in Hypocellular Bone Marrow Disorders.

Authors:  Pooja Sharma; Anshu Palta; Anita Tahlan; Manveen Kaur; Ram Singh
Journal:  J Lab Physicians       Date:  2021-08-24
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.